- Home
- LEXX vs ABVC Comparison
LEXX vs ABVC Comparison
Compare LEXX & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- ABVC
- Stock Information
- Founded
- LEXX 2004
- ABVC 2015
- Country
- LEXX Canada
- ABVC United States
- Employees
- LEXX N/A
- ABVC N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- ABVC Health Care
- Exchange
- LEXX Nasdaq
- ABVC Nasdaq
- Market Cap
- LEXX 19.6M
- ABVC 22.1M
- IPO Year
- LEXX N/A
- ABVC N/A
- Fundamental
- Price
- LEXX $0.95
- ABVC $3.39
- Analyst Decision
- LEXX Strong Buy
- ABVC
- Analyst Count
- LEXX 1
- ABVC 0
- Target Price
- LEXX $5.00
- ABVC N/A
- AVG Volume (30 Days)
- LEXX 101.8K
- ABVC 713.8K
- Earning Date
- LEXX 07-14-2025
- ABVC 08-13-2025
- Dividend Yield
- LEXX N/A
- ABVC N/A
- EPS Growth
- LEXX N/A
- ABVC N/A
- EPS
- LEXX N/A
- ABVC N/A
- Revenue
- LEXX $615,923.00
- ABVC $508,383.00
- Revenue This Year
- LEXX $6.04
- ABVC $735.18
- Revenue Next Year
- LEXX $8.36
- ABVC N/A
- P/E Ratio
- LEXX N/A
- ABVC N/A
- Revenue Growth
- LEXX 49.85
- ABVC 1904.43
- 52 Week Low
- LEXX $0.79
- ABVC $0.40
- 52 Week High
- LEXX $4.38
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- LEXX 43.10
- ABVC 58.50
- Support Level
- LEXX $0.79
- ABVC $3.30
- Resistance Level
- LEXX $0.90
- ABVC $3.92
- Average True Range (ATR)
- LEXX 0.04
- ABVC 0.65
- MACD
- LEXX 0.01
- ABVC -0.04
- Stochastic Oscillator
- LEXX 60.87
- ABVC 41.57
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.